



US008399508B2

(12) **United States Patent**
Singh et al.

(10) **Patent No.:** **US 8,399,508 B2**
(45) **Date of Patent:** ***Mar. 19, 2013**

- (54) **OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION**
- (75) Inventors: **Onkar N. Singh**, Arlington, TX (US); **G. Michael Wall**, Fort Worth, TX (US); **Rajni Jani**, Fort Worth, TX (US); **Masood A. Chowhan**, Arlington, TX (US); **Wesley Wehsin Han**, Arlington, TX (US)
- (73) Assignee: **Alcon Pharmaceuticals Ltd.**, Fribourg (CH)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 90 days.

This patent is subject to a terminal disclaimer.

4,778,596 A	10/1988	Linder et al.
4,871,865 A	10/1989	Lever, Jr. et al.
4,923,892 A	5/1990	Lever, Jr. et al.
5,116,863 A	5/1992	Oshima et al.
5,164,194 A	11/1992	Hettche
5,443,833 A	8/1995	Clark et al.
5,478,565 A	12/1995	Geria
5,482,706 A	1/1996	Igari et al.
5,641,805 A	6/1997	Hayakawa et al.
6,054,462 A	4/2000	Francois et al.
6,146,622 A	11/2000	Castillo et al.
6,174,914 B1	1/2001	Yanni et al.
6,207,684 B1	3/2001	Aberg
6,274,626 B1	8/2001	Jonasse et al.
6,316,483 B1	11/2001	Haslwanger et al.
6,333,044 B1	12/2001	Santus et al.
6,995,186 B2	2/2006	Castillo et al.
2001/0056093 A1	12/2001	Yanni
2006/0110328 A1	5/2006	Cagle et al.

- (21) Appl. No.: **13/173,608**
- (22) Filed: **Jun. 30, 2011**
- (65) **Prior Publication Data**
US 2011/0306659 A1 Dec. 15, 2011

Related U.S. Application Data

- (63) Continuation of application No. 11/703,373, filed on Feb. 7, 2007, now Pat. No. 7,977,376, which is a continuation-in-part of application No. 11/079,996, filed on Mar. 15, 2005, now Pat. No. 7,402,609, which is a continuation of application No. 10/175,106, filed on Jun. 19, 2002, now Pat. No. 6,995,186.
- (60) Provisional application No. 60/301,315, filed on Jun. 27, 2001.
- (51) **Int. Cl.**
A61K 31/335 (2006.01)
- (52) **U.S. Cl.** **514/450; 424/810**
- (58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,407,791 A	10/1983	Stark
4,749,700 A	6/1988	Wenig

FOREIGN PATENT DOCUMENTS

EP	0048023	3/1982
EP	0214779	3/1987
EP	0235796	9/1987
JP	61926	3/1995
WO	WO0003705	1/2000
WO	WO0121209	3/2001

(Continued)

OTHER PUBLICATIONS

Church, Martin K., Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-Allergic Drugs?, Agents and Actions, 1986, pp. 288-293, vol. 18, 3/4.


(Continued)

Primary Examiner — Brian Gullede
Assistant Examiner — Isaac Shomer
(74) *Attorney, Agent, or Firm* — Patrick M. Ryan

(57) **ABSTRACT**

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.

2 Claims, 6 Drawing Sheets



FOREIGN PATENT DOCUMENTS

WO	WO0121210	3/2001
WO	WO0135963	5/2001
WO	WO0154687 A1	8/2001
WO	WO0230395 A1	4/2002
WO	WO03002093 A1	1/2003
WO	WO2004043470 A1	5/2004

OTHER PUBLICATIONS

Clegg, L.S., et al., Histamine Secretion From Human Skin Slices Induced by Anti-IgR and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutamol, *Clinical Allergy*, 1985, pp. 321-328, vol. 15.

Hamilton, S.A., et al., Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals, *Clinical and Experimental Allergy*, 1994, pp. 955-959, vol. 24.

Ikeda, Katsuhisa, et al., Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands. *Int. Arch. Allergy Immunol.*, 1995, pp. 157-162, vol. 106.

Irani, Anne-Marie A., et al., Mast Cell Heterogeneity, *Clinical and Experimental Allergy*, 1989, pp. 143-155, vol. 19.

Kamei, C., et al.; Effect of (Z)-11-[3-(Dimethylamino)propylidene]-6, 11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs, *Arzneimittelforschung*, 1995, pp. 1005-1008, vol. 45(9).

Kamei, Chiaki, et al., Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs, *Atarashii Ganka*, 1994, pp. 603-605, vol. 11(4) (abstract only).

Ohshima, Etsuo, et al., Synthesis and Antiallergic Activity of 11-(Aminoalkylidene)-6, 11, dihydrodibenz[b,e]oxepin Derivatives, *J. Medicinal Chemistry*, 1992, pp. 2074-2054, vol. 35(11).

Pearce, Cheryl A., et al., Effect of Disodium Cromoglycate on Antigen-Evoked Histamine Release From Human Skin, *Clinical Exp. Immunol.*, 1974, pp. 437-440, vol. 17.

Pujara, et al., Effects of Formulation Variables on Nasal Epithelial Cell Integrity: Biochemical Evaluations, *International J. of Pharmaceutics*, 1995, pp. 197-203, vol. 114.

Sharif, N.A., et al., Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases, *J. of Pharmacology and Experimental Therapeutics*, 1996; pp. 1252-1261, vol. 278(3).

Sharif, N.A., et al., Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-Histaminic/Anti-Allergic Drug for Use in Allergic Compounds, *Investigative Ophthalmology & Visual Science*, 1996, p. 1027, Vol. 37(3) (abstract only).

Siraganian, Reuben P., An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine, *Anal. Biochem.*, 1974, pp. 383-394, vol. 57.

Spitalny, L., et al., Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis, *Investigative Ophthalmology & Visual Science*, 1996, p. 593, vol. 37(3) (abstract only).

LB Schwartz, TF Huff. "Mast Cells." *The Lung*, Scientific Foundation, 1991, Ch. 3.4.11, Raven Press, Ltd., New York, pp. 601-615.

Yanni; J.M., et al., The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-Allergic/Anti-Histamine Agent, *Investigative Ophthalmology & Visual Science*, 1996, p. 1028, vol. 37(3) (abstract only).

Zhang, Ming-Qiang, et al., Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic Activity, *Chirality*, 1994, p. 631-641, vol. 6(8).

Astelin® Nasal Spray Product Insert, Jun. 7, 2002, 11 printed pages.
Ratner, P.H., et al., Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray for the Treatment of Seasonal Allergic Rhinitis to Mount Cedar, *Annals Allergy Asthma Immunol.*, 2005, pp. 474-479, vol. 95.

Berge, S. M., et al., Pharmaceutical Salts, *Journal of Pharmaceutical Science*, Jan. 1977, pp. 1-19, vol. 66, No. 1.




Fig. 1A




Fig. 1B




Fig. 2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.